TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.…
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics (NASDAQ: TCRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 138 employees.
The shares were at 0.1459 USD on 20 November 2026, down 86.6% over 52 weeks. Its 52-week range is 0.1400 USD to 1.470 USD: the price is 90.1% below the high and 4.2% above the low.
Its market capitalisation is 9.89M USD.
TScan Therapeutics reports return on equity of -105.4% and revenue down 65.8% year over year.
It holds more cash than debt, a net cash position of 9.26M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.